Monday 15 August 2016, Amsterdam
The report, now available on ASDReports, "Clinical Trial Management System Market by End-user (Pharmaceutical & Biotechnology, Medical Device Companies, CROs), Delivery Mode (Web Hosted, On-premise, & Cloud-based), Type (Enterprise, & Site), Component (Software, & Service) - Global Forecast to 2021", that analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
This report studies the global CTMS market over the forecast period of 2016 to 2021. The market is expected to reach USD 920.2 Million by 2021, at CAGR of 11.5% from 2016 to 2021. Factors such as increasing research and development expenditure of life science and clinical research industries, rising number of clinical trials, increasing number of new product launches, and increasing customer base owing to the rising adoption of CTMS solutions are driving the growth of the global CTMS market. On the other hand, factors such as lack of skilled professionals to operate advanced CTMS and budget constraints of small- and medium-sized pharmaceutical and biotechnology companies and small CROs are restricting the growth of the global CTMS market.
This report covers four major end users, namely, pharmaceutical and biopharmaceutical companies, contract research organizations, medical device companies, and others. The pharmaceutical and biopharmaceutical companies segment is expected to account for the largest share of the CTMS market in 2016. The large share of this segment can be attributed to the increasing adoption of CTMS software during drug clinical trials by pharmaceutical and biopharmaceutical companies. The contract research organizations segment is estimated to witness the highest growth during the forecast period, primarily due to the rising trend of clinical trial outsourcing to CROs.
On the basis of delivery mode, the global CTMS market is segmented into web-based (on-demand), licensed enterprise (on-premise), and cloud-based (SaaS) segments. The cloud-based (SaaS) segment is estimated to witness the highest growth during the forecast period, primarily due to the rising adoption of cloud-based solutions in medical research studies owing to various benefits offered by them such as low cost, high security, privacy, and easy accessibility from any device.
On the basis of component, the CTMS market is segmented into software and services. The software segment is expected to account for the largest share of the global CTMS market in 2016, and is also expected to grow at the highest CAGR during the forecast period. This high growth is mainly attributed to the fierce competition in the pharmaceutical industry to introduce cost-effective novel drugs in the market, increased adoption of CTMS due to advantages provided by the same among various end users, and increasing number of clinical trials.
The CTMS market is further segmented into enterprise CTMS and site CTMS on the basis of type. The enterprise CTMS segment is expected to command the largest share of the global CTMS market in 2016, and is expected to grow at the highest CAGR in the forecast period. This is attributed to the widespread adoption of enterprise CTMS by majority of the end users.
North America commands the largest share of the global CTMS market in 2016, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021. Factors such as increase in outsourcing of clinical trials, availability of large and diverse patient population, presence of less stringent regulatory guidelines as compared to developed nations, and comparatively less cost of conducting clinical trials in APAC countries are driving growth of the market.
Oracle Corporation (U.S.), Medidata Solutions, Inc. (U.S.), and PAREXEL International Corporation (U.S.) are the major players in the global CTMS market.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : email@example.com
back to News